Small-Cap Surge: Breakouts, Breakdowns, and Future Trends (LTRY, GTBP, DM, LIXT, HSDT)

Mastering the rollercoaster of penny stocks demands a sharp eye for upcoming catalysts and pivotal levels that can make or break their path. In this watchlist, we unravel the intricacies of these five high-risk, high-reward penny stocks, shedding light on the imminent catalysts and key levels that demand attention from savvy investors.

Lottery.com, Inc. (NASDAQ: LTRY) - Lottery.com, Inc. shares ended last week's trading session up 5%, closing at $1.29. In their latest quarterly filing, the company announced that on September 28, 2023, they entered into a Stock Purchase Agreement with the shareholders of Nook Holdings Limited ("Nook"), a private limited company in Abu Dhabi, UAE. The total purchase price is approximately $2.314 million. The company made three payments totaling $137,500 in the fourth quarter and expects the transaction to close by June 30, 2024, or as otherwise agreed by the parties. Nook is known for its innovative co-working solutions in Dubai and has secured 200 licenses for individuals and companies in the sports, health, and wellness sectors seeking access to Dubai and the broader Middle Eastern market. Additionally, as reported on Form 8-K filed with the SEC on February 21, 2024, the company entered into a Memorandum of Understanding (MOU) with S&MI Ltd. ("SportLocker.com") on February 15, 2024. According to the MOU, Lottery.com agreed to pay S&MI Ltd. shareholders a total of $1,000,000 in restricted common stock at a valuation of $3.00 per share. The terms and conditions of the MOU will be incorporated into a definitive agreement, with a closing date on or before June 30, 2024, or as otherwise agreed by the parties. As we await further updates from the company, we will be watching for a possible resistance break at the $1.30 level.

--

GT Biopharma Inc. (NASDAQ: GTBP) - GT Biopharma Inc. shares closed last week's trading session up 2%, ending at $2.92. In May, the company announced its first quarter 2024 financial results and provided a corporate update. Key highlights include the anticipated IND clearance for GTB-3650, a second-generation nanobody TriKE® for treating CD33+ leukemia, expected in Q2 2024, and the initiation of a Phase 1 trial for GTB-3650 in the second half of 2024. Additionally, the company plans to start a Phase 1 dose escalation basket trial evaluating GTB-5550 in six solid tumor cancers: prostate, breast, head and neck, ovarian, lung, and GI. As of March 31, 2024, GT Biopharma had approximately $9.81 million in cash, enough to fund operations into 2025. Towards the end of May, GT Biopharma entered into definitive securities purchase agreements for the sale of 740,000 shares of common stock at $4.35 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the company issued warrants to purchase up to 740,000 shares of common stock at an exercise price of $4.35 per share. Last week, the company filed an S-1 prospectus relating to the resale or other disposition of up to 740,000 shares of common stock issuable upon exercise of these warrants. The Annual Meeting of Stockholders is scheduled for June 25, 2024, at 9:00 AM Pacific Time. As we await further updates from the company, we will be watching for a potential resistance break at the $3.05 level.

--

Desktop Metal, Inc. (NYSE: DM) - Desktop Metal, Inc. shares ended last week's trading session slightly down, closing at $4.13. This month, the company announced the launch of the new PureSinter™ Furnace, designed for high-purity, one-run debinding and sintering of powder metal parts. PureSinter is compatible with parts 3D printed using Additive Manufacturing methods like Bound Metal Deposition® (BMD) and Binder Jetting (BJT), as well as traditional Metal Injection Molding (MIM) and Press and Sinter (PM) techniques. Standard shipments of the PureSinter Furnace, which is validated with 14 metal powder and binder combinations, are set to begin in Q3. The global debut of the Desktop Metal PureSinter Furnace will take place June 25-27 in Los Angeles at Rapid + TCT, North America's largest additive manufacturing and industrial 3D printing event. As we await further updates, we will be watching for a possible resistance break at the $4.25 level.

--

Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) - Lixte Biotechnology Holdings, Inc. shares ended last week's trading session up 2%, closing at $2.54. This month, the company announced a Clinical Trial Agreement with the Netherlands Cancer Institute (NKI) to conduct a Phase 1b/2 clinical trial of their protein phosphatase inhibitor, LB-100, in combination with atezolizumab, a PD-L1 inhibitor from F. Hoffman-La Roche Ltd. (Roche), for patients with metastatic colon cancer. Under the Agreement, Lixte will provide LB-100, while Roche, through a separate agreement with NKI, will supply atezolizumab and financial support for the trial. The study includes a dose escalation phase to determine the recommended Phase 2 dose (RP2D) of LB-100 combined with atezolizumab, followed by a dose expansion phase to further assess the clinical activity, safety, tolerability, and pharmacokinetics/dynamics of the combination. The trial is set to begin by June 30, 2024, with patient enrollment expected to take up to 24 months, targeting a maximum of 37 patients with advanced colorectal cancer. As we await further updates, we will be watching for a potential resistance break at the $2.60 level.

--

Helius Medical Technologies, Inc. (NASDAQ: HSDT) - Helius Medical Technologies, Inc. shares ended last week's trading session up 1%, closing at $0.97. This month, the company announced the completion of site participation enrollment for its U.S. stroke registrational program, adding REHABOLOGYM, Neurology Center of New England (NCNE), and MGH Institute of Health Professions (MGH-IHP). This program, which also includes Brooks Rehabilitation and Shepherd Center, aims to assess the effects of cranial-nerve non-invasive neuromodulation (CN-NINM) using PoNS Therapy® on gait and dynamic balance in chronic stroke survivors. REHABOLOGYM, led by Avrielle Rykman Peltz, M.A., OTR/L, and Dr. Jay Lombard, D.O., has already enrolled six subjects and expects to reach at least ten patients by early July. NCNE and MGH-IHP joined the study in May and June, respectively, with enrollment starting in July. Brooks Rehabilitation began enrollment in April and currently has three participants, while Shepherd Center enrolled two participants in May and expects to add two more by the end of June. Helius aims to enroll at least thirty patients in this open-label study across all sites by the end of the third quarter. As we await further updates from the company, we will be watching for a potential resistance break at the $1.10 level.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.